{"id":1885,"date":"2002-12-01T12:06:00","date_gmt":"2002-12-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/pravastatin-reduziert-kardiovaskulaere-ereignisse-auch-bei-alten-menschen-mit-erhoehtem-risiko-die-prosper-studie"},"modified":"2022-03-17T14:10:16","modified_gmt":"2022-03-17T13:10:16","slug":"pravastatin-reduziert-kardiovaskulaere-ereignisse-auch-bei-alten-menschen-mit-erhoehtem-risiko-die-prosper-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/pravastatin-reduziert-kardiovaskulaere-ereignisse-auch-bei-alten-menschen-mit-erhoehtem-risiko-die-prosper-studie","title":{"rendered":"Pravastatin reduziert kardiovaskul\u00e4re Ereignisse auch bei alten Menschen mit erh\u00f6htem Risiko. Die PROSPER-Studie"},"content":{"rendered":"<p>Obwohl auch fr\u00fchere Langzeit-Behandlungsstudien mit Simvastatin (Denan, Zocor) und Pravastatin (Mevalotin protect, Pravasin protect) bereits erkennen lie\u00dfen, da\u00df diese Statine nicht nur bei mittelalten, sondern auch bei alten Menschen die Komplikationsrate einer Arteriosklerose (Herzinfarkte, Schlaganf\u00e4lle) reduzieren k\u00f6nnen, f\u00fchrte die PROSPER study group in Schottland, Irland und Holland ab 1997 eine erneute Studie durch, in der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Obwohl auch fr\u00fchere Langzeit-Behandlungsstudien mit Simvastatin (Denan, Zocor) und Pravastatin (Mevalotin protect, Pravasin protect) bereits erkennen lie\u00dfen, da\u00df diese Statine nicht nur bei mittelalten, sondern auch bei alten Menschen die Komplikationsrate einer Arteriosklerose (Herzinfarkte, Schlaganf\u00e4lle) reduzieren k\u00f6nnen, f\u00fchrte die PROSPER study group in Schottland, Irland und Holland ab 1997 eine erneute Studie durch, in der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[60,451,449,71,68,455,453,498,456,65,801,3126,56,443],"class_list":["post-1885","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-apoplektischer-insult","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-herzinfarkt","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-pravastatin","tag-prosper-studie","tag-schlaganfall","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1885"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1885\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}